Euprotec Collaborat?es with Cantab Anti-Infec?tives to Develop Novel Antibiotic?s
Euprotec Ltd, a specialty life sciences and drug discovery CRO, has entered into an alliance with Cantab Anti-infectives as they seek to develop improved antibiotics to treat multidrug resistant Gram negative bacterial infections.
Euprotec will assist in accelerating Cantab’s drug development programme following its £2.3m funding award from the Technology Strategy Board’s Biomedical Catalyst. The goal of the programme is to develop improved therapeutics based on the polymyxin core. Polymyxins are an important class of antibiotics with a unique and important target and are currently viewed as a last resort when treating severe infections due to multidrug resistant Gram negative bacteria. The polymyxins have advanced little since they were developed more than 50 years ago and this funding provides an important opportunity to generate a drug with an improved therapeutic index and lower propensity for development of resistance.
Euprotec will provide Cantab with its microbiology expertise and resources to facilitate the rapid identification and optimisation of a new drug candidate. The company will use its specialist biology platform combined with its highly characterised collection of bacteria in order to optimise the potency and efficacy of new compounds. The approach will allow profiling of PKPD parameters to permit translation of preclinical data to clinical trials.
Dr Lloyd Payne, chief executive of Euprotec said: “We are thrilled that Cantab has selected Euprotec as its infectious disease biology partner for this programme. Multidrug resistant Gram negative bacterial infections pose an enormous threat, and we look forward to working with Cantab to realise the exciting potential of their antibiotic platform.”
Dr Mike Dawson, chief executive of Cantab said: “We selected Euprotec as our primary biology partner for this programme due to its strong reputation for delivery in the infectious disease therapeutic area as well as the depth and breadth of their portfolio and expertise.
“The specialist knowledge and technical skills that Euprotec provides will supplement our in-house research team perfectly and we are looking forward to working with them as we progress our discovery and development programme.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance